Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
-
Value Traded
-
Short % Float
-
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BIORQ Catalyst Timeline
Dated clinical, regulatory and corporate events for Biora Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biora Therapeutics, Inc.
6Total events
2Upcoming
0Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 1
▲Ethics Committee ApprovalBioJetTrial
HREC approval for first-in-human study of BioJet capsule in Australia
Past FDA Catalysts and PDUFA Decisions
How BIORQ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BIORQ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in BIORQ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BIORQ for Q2 2026. | ||||
Ownership Trends
BIORQ Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
155.9K
Shares Sold Short
0.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
351
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BIORQ ranks across every disease it competes in
Competitive Position is a premium feature
See how BIORQ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBIORQ News
-BIORQ
Nov 4, 2026▲ +9900%on this news
Biora Therapeutics Receives Approval for First-in-Human Trial of BioJet™ Oral Biologic Delivery Capsule
Biora Therapeutics has received HREC approval for its first-in-human trial of the BioJet capsule in Australia. The study will assess the safety and pharmacokinetics of adalimumab delivered via the capsule compared to traditional injections. The company aims to begin dosing by December, potentially transforming how biologics are administered.
Read more →-BIORQ
Sep 10, 2026Biora Therapeutics to Initiate First Human Trial of BioJet™ Oral Biologic Delivery Capsule
Biora Therapeutics announced plans to initiate a first-in-human trial for its BioJet capsule, designed for oral delivery of adalimumab. The trial will evaluate safety and pharmacokinetics compared to traditional injections. If successful, this could lead to a regulatory filing in 2027, potentially transforming biologic drug delivery.
Read more →About Biora Therapeutics, Inc.
BIOPHARMAWATCH ELITE
Trade the next BIORQ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime